{
      "Rank": 350,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Allogeneic bone marrow-derived mesenchymal stem cells (10^6/kg) from third party donors is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21.Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone.\n\nThe third-party MSCs have no similar HLA alleles of kidney donors, and have no HLA alleles specific to preformed anti-HLA antibodies in recipients prior to KTx.",
            "Placebo (saline) is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21. Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone."
      ],
      "ArmGroupInterventionName": [
            "Other: bone marrow-derived mesenchymal stem cells",
            "Drug: Induction therapy (ATG or Basiliximab)",
            "Drug: Maintenance therapy (Low-dose CNI + MPA + steroids)",
            "Other: Saline",
            "Drug: Induction therapy (ATG or Basiliximab)",
            "Drug: Maintenance therapy (Low-dose CNI + MPA + steroids)"
      ],
      "ArmGroupLabel": [
            "MSCs group",
            "Control group"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT02561767"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "This study is designed to determine the efficacy and safety of allogeneic bone marrow-derived mesenchymal stem cells in kidney transplantation from Chinese donation after citizen's death (DCD). A pair uremia patients receiving kidney grafts from a same donor are randomized into two groups: MSCs group and control group. Besides routine induction therapy (ATG or Basiliximab) and maintenance immunosuppressive drugs (low-dose Tacrolimus + MPA + prednisone), patients in MSCs group are administered MSCs treatment (1*10^6/kg). Allogeneic bone marrow-derived MSCs (1*10^6/kg) are given intravenously at day 0 (post renal reperfusion during surgery), day 7, day 14 and day 21. The renal allograft function, rejection, patient/graft survival and severe adverse events within 12 months post-transplant are monitored."
      ],
      "BriefTitle": [
            "Effect of BM-MSCs in DCD Kidney Transplantation"
      ],
      "CentralContactEMail": [
            "wangchx@mail.sysu.edu.cn",
            "liulshan@mail.sysu.edu.cn"
      ],
      "CentralContactName": [
            "Changxi Wang, M.D., Ph.D",
            "Longshan Liu, M.D., Ph.D"
      ],
      "CentralContactPhone": [
            "86-20-87333428",
            "86-20-87306082"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [
            "OTHER"
      ],
      "CollaboratorName": [
            "Second Affiliated Hospital of Guangzhou Medical University"
      ],
      "CompletionDate": [
            "October 2017"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Kidney Transplantation",
            "Acute Kidney Tubular Necrosis"
      ],
      "ConditionAncestorId": [
            "D000010335",
            "D000058186",
            "D000051437",
            "D000007674",
            "D000014570"
      ],
      "ConditionAncestorTerm": [
            "Pathologic Processes",
            "Acute Kidney Injury",
            "Renal Insufficiency",
            "Kidney Diseases",
            "Urologic Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC23",
            "All",
            "BC14",
            "BXS",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Symptoms and General Pathology",
            "All Conditions",
            "Heart and Blood Diseases",
            "Urinary Tract, Sexual Organs, and Pregnancy Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Necrosis",
            "Acute Kidney Tubular Necrosis"
      ],
      "ConditionBrowseLeafId": [
            "M11436",
            "M9695",
            "M5997",
            "M17251",
            "M9858",
            "M28151",
            "M25871",
            "M9850",
            "M16471",
            "T170"
      ],
      "ConditionBrowseLeafName": [
            "Necrosis",
            "Ischemia",
            "Death",
            "Reperfusion Injury",
            "Kidney Tubular Necrosis, Acute",
            "Acute Kidney Injury",
            "Renal Insufficiency",
            "Kidney Diseases",
            "Urologic Diseases",
            "Acute Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000007683",
            "D000009336"
      ],
      "ConditionMeshTerm": [
            "Kidney Tubular Necrosis, Acute",
            "Necrosis"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Single"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant"
      ],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nPrimary kidney transplantation\nReceiving induction therapy and combined immunosuppressive regimens (CNIs + MPA + steroids)\nPatient is willing and capable of giving written informed consent for study participation and able to participate in the study for 12 months\n\nExclusion Criteria:\n\nSecondary kidney transplantation\nCombined or multi-organ transplantation\nWomen who are pregnant, intend to become pregnant in the next 1 years, breastfeeding, or have a positive pregnancy test on enrollment or prior to study medication administration\nPanel reactive antibody (PRA)>20%\nCDC crossmatch is positive\nDonors or recipients are known hepatitis C antibody-positive or polymerase chain reaction (PCR) positive for hepatitis C\nDonors or recipients are known hepatitis B surface antigen-positive or PCR positive for hepatitis B\nDonors or recipients are known human immunodeficiency virus (HIV) infection\nPatients with active infection\nRecipients with a history of substance abuse (drugs or alcohol) within the past 6 months, or psychotic disorders that are not capable with adequate study follow-up.\nPatients with severe cardiovascular dysfunction\nWBC<3*10^9/L or RBC <5g/dL\nHighly allergic constitution or having severe history of allergies.\nPatients with active peptic ulcer disease, chronic diarrhea, or gastrointestinal problem affect absorption\nPatients with a history of cancer within the last 5 years\nPrisoner or patients compulsorily detained (involuntarily incarcerated) for treatment or either a psychiatric or physical (e.g. infectious disease) illness"
      ],
      "EnrollmentCount": [
            "120"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000007166",
            "D000007155",
            "D000045505",
            "D000065095",
            "D000004791",
            "D000045504",
            "D000000903",
            "D000000970",
            "D000000904",
            "D000000995",
            "D000000900",
            "D000000890"
      ],
      "InterventionAncestorTerm": [
            "Immunosuppressive Agents",
            "Immunologic Factors",
            "Physiological Effects of Drugs",
            "Calcineurin Inhibitors",
            "Enzyme Inhibitors",
            "Molecular Mechanisms of Pharmacological Action",
            "Antibiotics, Antineoplastic",
            "Antineoplastic Agents",
            "Antibiotics, Antitubercular",
            "Antitubercular Agents",
            "Anti-Bacterial Agents",
            "Anti-Infective Agents"
      ],
      "InterventionArmGroupLabel": [
            "MSCs group",
            "Control group",
            "Control group",
            "MSCs group",
            "Control group",
            "MSCs group"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Infe",
            "ANeo",
            "All",
            "Infl"
      ],
      "InterventionBrowseBranchName": [
            "Anti-Infective Agents",
            "Antineoplastic Agents",
            "All Drugs and Chemicals",
            "Anti-Inflammatory Agents"
      ],
      "InterventionBrowseLeafAsFound": [
            "POC",
            "Cardiac",
            "Genotype 1"
      ],
      "InterventionBrowseLeafId": [
            "M11280",
            "M9336",
            "M3377",
            "M18102",
            "M13273",
            "M9364",
            "M3431",
            "M1830",
            "M9353",
            "M29605",
            "M3374",
            "M3376",
            "M3463",
            "M3366"
      ],
      "InterventionBrowseLeafName": [
            "Mycophenolic Acid",
            "Immunoglobulins",
            "Antibodies",
            "Tacrolimus",
            "Prednisone",
            "Immunosuppressive Agents",
            "Antilymphocyte Serum",
            "Basiliximab",
            "Immunologic Factors",
            "Calcineurin Inhibitors",
            "Anti-Bacterial Agents",
            "Antibiotics, Antitubercular",
            "Antitubercular Agents",
            "Anti-Infective Agents"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "high",
            "low",
            "low",
            "low",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "BM-MSCs is harvested from third-party health volunteer donors.",
            "Saline as placebo of MSCs",
            "ATG, antithymocyte globulin; Basiliximab, anti-CD25 mAb. Recipients receive ATG or Basiliximab as induction therapy in both MSCs group and control group.",
            "Maintenance immunosuppressive therapy consists of low-dose tacrolimus and mycophenolic acid and steroids. Recipients receive the same maintenance therapy in both MSCs group and control group."
      ],
      "InterventionMeshId": [
            "D000009173",
            "D000016559",
            "D000077552"
      ],
      "InterventionMeshTerm": [
            "Mycophenolic Acid",
            "Tacrolimus",
            "Basiliximab"
      ],
      "InterventionName": [
            "bone marrow-derived mesenchymal stem cells",
            "Saline",
            "Induction therapy (ATG or Basiliximab)",
            "Maintenance therapy (Low-dose CNI + MPA + steroids)"
      ],
      "InterventionOtherName": [
            "BM-MSCs",
            "ATG or Basiliximab",
            "Low-dose tacrolimus + Mycophenolic acid (MPA) + steroids"
      ],
      "InterventionType": [
            "Other",
            "Other",
            "Drug",
            "Drug"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "kidney transplantation",
            "mesenchymal stem cell",
            "donation after citizen's death",
            "ischemia reperfusion injury",
            "renal function recovery"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [
            "Not yet recruiting"
      ],
      "LastUpdatePostDate": [
            "September 28, 2015"
      ],
      "LastUpdatePostDateType": [
            "Estimate"
      ],
      "LastUpdateSubmitDate": [
            "September 25, 2015"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "First Affiliated Hospital, Sun Yat-Sen University"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Guangzhou"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "China"
      ],
      "LocationFacility": [
            "The First Affiliated Hospital, Sun Yat-sen University"
      ],
      "LocationState": [
            "Guangdong"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "510080"
      ],
      "MaximumAge": [
            "65 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "The Efficacy and Safety of Bone Marrow-derived Mesenchymal Stem Cells in Kidney Transplantation From Chinese Donation After Citizen Death (DCD): A Multi-center Randomized Controlled Trial"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "First Affiliated Hospital, Sun Yat-Sen University"
      ],
      "OrgStudyId": [
            "MSCs-KTx-DCD-150924"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "First Affiliated Hospital, Sun Yat-Sen University"
      ],
      "OverallOfficialName": [
            "Changxi Wang, M.D., Ph.D"
      ],
      "OverallOfficialRole": [
            "Study Chair"
      ],
      "OverallStatus": [
            "Unknown status"
      ],
      "OversightHasDMC": [
            "No"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "October 2016"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "eGFR at one month post-transplant"
      ],
      "PrimaryOutcomeMeasure": [
            "Estimated glomerular filtration rate"
      ],
      "PrimaryOutcomeTimeFrame": [
            "1 month"
      ],
      "ReferenceCitation": [
            "Peng Y, Ke M, Xu L, Liu L, Chen X, Xia W, Li X, Chen Z, Ma J, Liao D, Li G, Fang J, Pan G, Xiang AP. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation. 2013 Jan 15;95(1):161-8. doi: 10.1097/TP.0b013e3182754c53. Erratum in: Transplantation. 2014 Mar 27;97(6):e37. Pan, Guanghui [added]."
      ],
      "ReferencePMID": [
            "23263506"
      ],
      "ReferenceType": [
            "background"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "First Affiliated Hospital, Sun Yat-Sen University"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Changxi Wang"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Director of Organ Transplant Center"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Principal Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "eGFR up to 12 months post-transplant"
      ],
      "SecondaryOutcomeMeasure": [
            "Incidence of slow graft function",
            "Incidence of delayed graft function",
            "Proportion of normal renal function recovery",
            "Time to renal function recovery",
            "Patient survival",
            "Renal graft survival",
            "Incidence of acute rejection",
            "Severe adverse events",
            "Estimated glomerular filtration rate"
      ],
      "SecondaryOutcomeTimeFrame": [
            "12 months",
            "12 months",
            "12 months",
            "12 months",
            "12 months",
            "12 months",
            "12 months",
            "12 months",
            "12 months"
      ],
      "SeeAlsoLinkLabel": [
            "Previous publication"
      ],
      "SeeAlsoLinkURL": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23263506"
      ],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "October 2015"
      ],
      "StartDateType": [],
      "StatusVerifiedDate": [
            "September 2015"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "September 28, 2015"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "September 25, 2015"
      ],
      "StudyFirstSubmitQCDate": [
            "September 25, 2015"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}